Frexalimab

Frexalimab is an experimental drug that is currently being studied for its potential use in the treatment of various autoimmune diseases. It is a monoclonal antibody that targets the interleukin-6 receptor (IL-6R), a protein that plays a key role in the immune response.

Mechanism of action

Frexalimab works by binding to the IL-6R, thereby blocking the interaction between IL-6 and its receptor. This prevents the activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, which is involved in the production of inflammatory cytokines.

Clinical trials

Several clinical trials have been conducted to evaluate the safety and efficacy of frexalimab in patients with autoimmune diseases. These trials have shown promising results, with patients experiencing a reduction in disease activity and an improvement in quality of life.

Potential applications

Frexalimab is being investigated for its potential use in the treatment of a variety of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease. It may also have potential applications in the treatment of other inflammatory conditions, such as psoriasis and asthma.

See also

• List of investigational drugs
• Monoclonal antibodies
• Autoimmune diseases